FDA Lifts Full Simufilam Hold, Clearing Planned Phase 2a Study in TSC Epilepsy

Key Facts

Filana Therapeutics said on September 22, 2026 that the FDA lifted the full clinical hold on simufilam for TSC-related epilepsy. The decision allows the company to move toward starting a planned Phase 2a proof-of-concept study in patients aged 12 to 55. Filana expects to begin screening prospective participants by the first quarter of 2027. Lifting the hold is not marketing approval and does not establish the drug’s safety or efficacy; it removes the regulatory barrier that prevented the proposed study from proceeding. For FLNA shareholders, the program therefore shifts from a regulatory standstill to an executable trial plan, while its clinical value remains unproven.

Filana designed the study as a 16-week, multicenter, randomized and double-blind trial testing two simufilam doses in patients with refractory TSC-related seizures. The company plans to operate 13 sites in the United States and enroll 40 participants aged 12 to 55. Participants completing the double-blind treatment period will be eligible for a 48-week extension study. Randomization and blinding reduce the influence of patient differences and investigator expectations when measuring seizures that may fluctuate over time. The targeted sample is therefore suited to proof-of-concept testing, but less capable of estimating a definitive treatment effect or supporting broad conclusions about every TSC patient.

The study is designed to assess safety, tolerability and pharmacokinetics, as well as seizure frequency, intensity and duration. Its disclosed measures also include nighttime seizures and sleep-related outcomes, extending the assessment beyond a daytime seizure count. Pharmacokinetics describes the body’s drug exposure over time and can help determine whether differences in response or adverse effects are related to dose. In Phase 2a, these measures can generate a signal for a development decision, but they are not confirmatory evidence of efficacy. Filana says the data may inform future studies in younger patients, which is a development possibility rather than a commitment to start another trial.

While the program was on hold, Filana engaged a clinical research organization, identified prospective study sites and began recruiting potential investigators. The company also said investigational drug supply is available, removing another operational task that could have delayed site initiation after regulatory clearance. Those preparations may shorten the interval between the hold lift and the opening of the first site, but they cannot guarantee the pace of patient recruitment. The specific timing guidance is for screening to begin by the first quarter of 2027, not for enrollment to finish or results to arrive by then. Site activation announcements followed by actual screening will therefore provide the first observable test of management’s ability to turn the regulatory decision into clinical execution.

Simufilam is an oral small molecule that Filana says is intended to modulate the activity of the filamin A protein. The move into human testing for this indication rests on findings from two preclinical mouse models, not evidence of efficacy in TSC patients. In a model associated with Yale research, simufilam reduced seizure frequency, while a separate TSC Alliance Preclinical Consortium study found dose-dependent attenuation of seizure-activity progression. Those results provide a scientific rationale for testing, but success in animals does not guarantee comparable target engagement or acceptable clinical benefit in humans. Filana holds an exclusive worldwide license to relevant Yale rights, with obligations that include potential milestone payments and royalties if the program eventually produces commercial sales.

TSC is a rare genetic disorder caused by mutations in TSC1 or TSC2 that affect the mTOR pathway and can produce tumors in multiple organs. Filana-filed materials say 80%-90% of TSC patients experience seizures and that TSC-related epilepsy affects about 45,000 people in the United States. Seizures begin in the first year of life for most patients, illustrating the early disease burden even though the current study excludes younger children. The company also reports that more than 60% of patients continue to have treatment-resistant seizures despite multiple available options. Because the initial cohort begins at age 12, any later expansion into younger patients would require an appropriate design and safety evidence rather than being inferred from the current group.

Simufilam has a longer clinical history in Alzheimer’s disease, an important part of the risk assessment for the new program. Between 2021 and 2025, the company enrolled 1,900 patients in two randomized Phase 3 studies, including 1,153 who received simufilam during the blinded phase. Filana reported in 2024 that RETHINK-ALZ missed its prespecified efficacy endpoints. In 2025, it said REFOCUS-ALZ also missed the specified endpoints and completed the Alzheimer’s program phaseout in the second quarter of 2025. Testing the same molecule in TSC rests on a different disease and therapeutic hypothesis, so the Alzheimer’s failures do not determine the epilepsy result, but they increase the importance of clear and reproducible human evidence.

Filana ended the first half with $82.7 million in cash and equivalents at June 30, 2026, down from $95.5 million at December 31, 2025. It recorded a second-quarter 2026 net loss of $8.6 million, or $0.18 per share. Net cash used in operations was $12.7 million in the first half, a direct measure of liquidity consumed by operating activities. On July 23, the company paid $31.25 million into escrow for a potential securities-litigation settlement, with the funds remaining restricted pending final court approval. Management said current working capital is sufficient for at least 12 months, although funding a longer clinical program will remain an important consideration for FLNA.

EL7 data shows FLNA closing September 22 at $1.03 after trading between $0.9011 and $1.30. The next observable catalysts are site announcements, the start of screening by the first quarter of 2027, the pace of enrollment and eventual safety or seizure data. The constructive case is that the hold lift reopens the path for the company’s principal drug asset, while the risks center on the small trial, the absence of demonstrated human efficacy in TSC and liquidity pressure. FLNA’s valuation after the regulatory development therefore depends on execution and forthcoming data, not on treating the hold lift itself as evidence that the drug will succeed.